期刊文献+

老年结肠癌辅助化疗研究现状与进展 被引量:5

下载PDF
导出
摘要 结肠癌是典型的老年病,随着人口老龄化时代的到来,这部份患者的治疗需求日益突出,但在现实医疗环境中,老年结肠癌患者术后存在治疗不足、治疗不当的问题。目前在世界范围内对老年结肠癌患者辅助化疗的研究较少,已有的研究支持对Ⅲ期老年患者进行氟尿嘧啶类单药辅助化疗,推荐的治疗时间应持续半年,药物的起始剂量建议适当减量,但现有的这些研究循证级别不高,今后应针对老年人群广泛开展包含药代动力学、药效学、方案优化选择及包含生物标志等内容的临床试验,为临床治疗提供充足的循证证据。
出处 《癌症进展》 2013年第2期140-143,151,共5页 Oncology Progress
  • 相关文献

参考文献25

  • 1Schrag D, Cramer LD, Bach PB, et al. Age and adjuvant chemotherapy use after surgery for stage llI colon cancer [J]. JNatlCancerlnst, 2001, 93 (11):850-857.
  • 2Potosky AL, Harlan LC, Kaplan RS, et al. Age, sex, anI racial differences in the use of standard adjuvant therapy fo1 colorectal cancer [ J]. J Clin Oneol, 2002, 20 (5) :1 1192 - 1202. /.
  • 3Kahn KL, Adams JL, Weeks JC, et al. Adjuvant chemo- therapy use and adverse events among older patients with stage m eolon cancer [J]. JAMA, 2010, 303 (11): 1037 - 1045.
  • 4Gross CP, McAvay GJ, Krumholz HM, et al. The effect of age and chronic illness on life expectancy after a diagnosis of colorectal cancer: implications for screening [ J]. Ann Intern Med, 2006, 145 (9) : 646 -653.
  • 5Sargent D J, Goldberg RM, Jacobson SD, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients [ J]. N Engl J Med, 2001,345 (15) : 1091 - 1097.
  • 6Jessup JM, Stewart A, Greene FL, et al. Adjuvant chemo- therapy for stage llI colon cancer: implications of race/eth- nicity, age, and differentiation [ J]. JAMA, 2005, 294 (21):2703 -2711.
  • 7Pasetto LM, Falci C, Basso U, et al. Adjuvant treatment for elderly patients with colon cancer. An observational study [ J ]Anticancer Res, 2008, 28 ( 4C ) : 2513 -2518.
  • 8Zuekerman IH, Rapp T, Onukwugha E, et al. Effect of age on survival benefit of adjuvant chemotherapy in elderly patients with Stage HI colon cancer [ J ]. J Am GeriatrSoc, 2009, 57 (8):1403-1410.
  • 9Wildes TM, Kallogjeri D, Powers B, et al. The Benefit of Adjuvant Chemotherapy in Elderly Patients with Stage m Co|orectal Cancer is Independent of Age and Comorbidity [J]. J Geriatr Oncol, 2010, 1 (2):48 -56.
  • 10van Steenbergen LN, Rutten HJ, Creemers GJ, et al. Large age and hospital-dependent variation in administra- tion of adjuvant chemotherapy for stage m colon cancer in southern Netherlands [J]. Ann Oncol, 2010, 21 (6): 1273 - 1278.

同被引文献50

  • 1Michael M, Zalcberg J, Gibbs P, et al. A phase I trial of imatinib in combination with mFOLFOX6-bevacizumab in patients with advanced colorectal cancer[J]. Cancer Chemother Pharmacol, 2013, 71(2):321-330.
  • 2Uncu D, Aksoy S, etin B, et al. Results of adjuvant FOLFOX regimens in stage Ⅲ colorectal cancer pa- tients: retrospective analysis of 667 patients[J]. Oncolo- gy, 2013, 84(4): 240-245.
  • 3Esch A, Coriat R, Perkins G, et al. Is there alternative to FOLFOX adjuvant chemo- therapy for stage Ⅲ colorec- tal cancer patients?[J]. La Press medicale, 2012, 41(1): 51-57.
  • 4Mizota A, Shitara K, Kondo C, et al. A case of heavily pretreated rectal cancer with disseminated intravascular coagulation that improved following reintroduction of FOLFOX plus bevacizumab[J]. Int J Clin Oncol, 2011,16(6): 766-769.
  • 5Bendell JC, Bekaii-Saab TS, Cohn AL, et al. Treatment patterns and clinical outcomes in patients with metastat- ic colorectal cancer initially treated with FOLFOX-Beva- cizumab or FOLFIRI-bevacizumab: Results from ARI- ES, a bevacizumab observational cohort study[J]. Oncol- ogist, 2012, 17(12): 1486-1495.
  • 6Zhi J, Chen E, Major P, et al. A multicenter, random- ized, open-label study to assess the steady-state pharma- cokinetics of bevacizttmab given with either XELOX or FOLFOX-4 in patients with metastatic colorectal cancer[J]. Cancer Chemother Pharmacol, 2011, 68(5): 1199-1206.
  • 7Landry JC, Feng Y, Cohen S J, et al. Phase 2 study of preoperative radiation with concurrent capecitabine, ox- aliplatin, and bevacizumab followed by surgery and postoperative 5- fluorouracil, leucovorin, oxaliplatin (FOLFOX), and bevacizumab in patients with locally advanced rectal cancer: ECOG 3204[J]. Cancer, 2013, 119(8): 1521-1527.
  • 8张宁宁,刘文超,薛研.人结肠癌组织中Raf-1的表达及其临床意义[J].中国肿瘤生物治疗杂志,2007,14(6):571-574. 被引量:5
  • 9吴学勇,高友福,谢芳,张正华.老年Ⅲ期结肠癌根治术后辅助化疗临床获益分析[J].肿瘤,2009,29(5):464-466. 被引量:8
  • 10朱广媛,李东华,张树范,李笑然.艾迪注射液的临床研究进展[J].中医药学报,2010,38(1):123-127. 被引量:70

引证文献5

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部